mTOR阻塞阻止了渐进的蛋白尿症,但在青春期之前,在肥胖的达尔盐敏感小鼠中诱导高血糖症
Sautan Mandal1, Andrea K Brown1, Ubong S Ekperikpe1
1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Experimental physiology
|October 28, 2025
概括
拉巴胺治疗通过阻断哺乳动物目标拉巴胺 (mTOR) 信号传递,抑制了肥胖大鼠的损伤. 这种干预减少了蛋白尿和改善了功能,表明了mTOR.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 代谢性疾病研究研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 哺乳动物的目标拉巴胺素 (mTOR) 活性在损伤期间在脏中增加.
- 达尔盐敏感瘦素受体突变 (SSLepR突变) 的老鼠表现出肥胖和脏异常.
- 了解mTOR在SSLepR突变鼠病中的作用至关重要.
研究的目的:
- 为了调查mTOR抑制剂拉巴素是否可以预防SSLepR突变大鼠的损伤.
- 在这个模型中阐明mTOR阻塞对代谢和脏参数的影响.
主要方法:
- 四周大的SS和SSLepR突变老鼠被用拉巴或载体治疗了4周.
- 评估的体重,血糖,血胰岛素和蛋白尿.
- 评估过,球/管状损伤以及糖共运输体2 (SGLT2) 的表达.
主要成果:
- 在SSLepR突变大鼠中,拉巴胺降低了体重和胰岛素,但引起了高血糖症.
- 蛋白尿症在SSLepR突变大鼠中被拉巴胺素显著降低.
- 拉巴胺改善了脏过,球/管状损伤,并在SSLepR突变大鼠中降低了SGLT2表达.
结论:
- mTOR信号传递是肥胖SSLepR突变大鼠脏代谢疾病的一个关键因素.
- 拉巴胺通过降低SGLT2活性,显示出预防肥胖相关过的潜力.
更多相关视频
10:31Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
604
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
911
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
